PARIS and CAMBRIDGE, Massachusetts, December 9, 2016 /PRNewswire/ --
Jai Patel appointed as Chief Medical Officer and Roger J. Garceau elected to the Board
Enterome SA, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, is pleased to announce the appointments of Jai Patel, Ph.D. as Chief Medical Officer (CMO), and Roger J. Garceau, MD as Non-executive Director. Drs Patel and Garceau bring significant experience in clinical pharmaceutical development and reinforce Enterome's leadership team as the Company progresses its lead therapeutic and diagnostic projects, including EB8018 for Crohn's disease, into and through clinical development.
Dr. Patel joins Enterome with over 25 years' industry experience and a strong background in international clinical development and regulatory affairs. He was most recently Chief Medical & Scientific Officer at NephroGenex, Inc. and, before that, spent over 20 years at GlaxoSmithKline where he held positions of increasing responsibility, serving as Vice President across R&D disciplines including clinical research, medical affairs and global regulatory affairs. He received his medical training at the University of London and is a member of the UK Royal College of Physicians.
Dr. Garceau brings over 30 years' of pharmaceutical development experience to Enterome. He previously served as CMO and Executive Vice President of Research & Development at NPS Pharmaceuticals, Inc. Prior to this, he held executive clinical and development roles at Sanofi-Aventis, Aventis and Pharmacia-Upjohn (Pfizer), where he contributed to a number of successful new pharmaceutical marketing applications. Dr. Garceau received his Doctorate of Medicine from the University of Massachusetts Medical School.
Commenting on his appointment, Jai Patel said: "I am pleased to join Enterome at such an important time for the Company. Enterome's unique metagenomics platform has enabled a new way of understanding the gut microbiome and its importance in human health. This platform is identifying novel targets and biomarkers to improve the diagnosis and management of serious diseases. Enterome's lead therapeutic candidate, EB8018, a novel small molecule candidate with a unique mode of action, in particular, is at an exciting stage of development as it approaches clinical trials as a potential new treatment for Crohn disease. The company is also building a pipeline of products with significant potential and I'm very excited to be working with the exceptional team to discover, develop and advance these in the coming years."
"Enterome has been expanding rapidly in recent months and continues to make steady progress advancing our pipeline. The appointments of Drs Patel and Garceau, in conjunction with the recent addition of Christophe Bonny as Chief Scientific Officer, significantly enhance the discovery and development, and international corporate development capabilities of the team, and give us great confidence for the further development of the company," added Pierre Belichard, CEO of Enterome.
Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.
Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; Bristol-Myers Squibb in immuno-oncology; and the Mayo Clinic and Geisinger hospitals in metabolic disorders.
The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €32 million from leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital & Omnes Capital) and strategic investors (Nestlé, Shire & INRA Transfert).
Additional information about Enterome is available through its website: http://www.enterome.com
Pierre Belichard, CEO
Tel. +33 1 75 77 27 87
David Dible / Mark Swallow / Marine Perrier
Citigate Dewe Rogerson
+44 207 638 9571 /email@example.com